DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Pentoxil (Pentoxifylline) - Summary

 
 



PENTOXIL SUMMARY

Pentoxil® (Pentoxifylline Extended-release Tablets, USP) for oral administration contain 400 mg of the active drug and the following inactive ingredients: D&C Red No. 27 Aluminum Lake, FD&C Blue No. 1 Aluminum Lake, hypromellose USP, magnesium stearate NF, polyethylene glycol NF, polysorbate 80 NF, povidone USP, silicon dioxide NF and titanium dioxide USP, in an extended-release formulation.

Pentoxil® (Pentoxifylline Extended-release Tablets, USP) is indicated for the treatment of patients with intermittent claudication on the basis of chronic occlusive arterial disease of the limbs. Pentoxil® can improve function and symptoms but is not intended to replace more definitive therapy, such as surgical bypass, or removal of arterial obstructions when treating peripheral vascular disease.


See all Pentoxil indications & dosage >>

NEWS HIGHLIGHTS

Published Studies Related to Pentoxil (Pentoxifylline)

Pentoxifylline decreases serum level of adhesion molecules in atherosclerosis patients. [2014]
with coronary artery disease (CAD)... CONCLUSION: Based on the results of our pilot study, administration of PTX in CAD

Pentoxifylline for intermittent claudication. [2012]
CONCLUSIONS: Given the generally poor quality of the published studies

Pentoxifylline improves nonalcoholic steatohepatitis: a randomized placebo-controlled trial. [2011.11]
CONCLUSION: PTX improved histological features of NASH compared to placebo. PTX was well tolerated in patients with NASH. Copyright (c) 2011 American Association for the Study of Liver Diseases.

Pentoxifylline decreases serum levels of tumor necrosis factor alpha, interleukin 6 and C-reactive protein in hemodialysis patients: results of a randomized double-blind, controlled clinical trial. [2011.10.03]
CONCLUSIONS: Pentoxifylline significantly decreased serum concentrations of TNF-alpha, IL-6 and CRP compared to placebo. Pentoxifylline could be a promising and useful strategy to reduce the systemic inflammation frequently observed in patients on HD.

Pentoxifylline (anti-tumor necrosis factor drug): effective adjuvant therapy in the control of ocular cicatricial pemphigoid. [2011.09]
PURPOSE: The detection of tumor necrosis factor-a (TNF-a) in conjunctiva affected by ocular cicatricial pemphigoid (OCP) may indicate that this cytokine plays an important role in its pathogenesis. The purpose of this randomized, controlled, comparative, blinded study was to evaluate the effectiveness of adding pentoxifylline as an anti-TNF-a drug to the well-documented therapy of steroids and cyclophosphamide in controlling OCP... CONCLUSIONS: The significantly increased level of serum TNF-a in OCP as compared to controls proves that TNF-a has an important role in the pathogenesis of this disease. The study illustrates that the addition of pentoxifylline to pulse steroid cyclophosphamide therapy is an effective, safe, and economical method in controlling OCP through directly reducing TNF-a levels, with long periods of remission as detected in our 18-month follow-up period.

more studies >>

Clinical Trials Related to Pentoxil (Pentoxifylline)

Pentoxifylline/Nonalcoholic Steatohepatitis (NASH) Study: The Effect of Pentoxifylline on NASH [Recruiting]

Prevention of Capsular Contracture Using Trental and Vitamin E [Recruiting]
The main purpose of this research study is to determine if the use of Trental and Vitamin E compared to Placebo (an inactive substance) will decrease the incidence and severity of contractures (shrinking and or hardening of tissue surrounding the implant) associated with breast implant reconstruction following radiation treatment. Another goal is to find out the impact that Trental and Vitamin E compared to Placebo may have on implant loss or need for surgical intervention in the setting of chest wall radiation after reconstruction. In addition, the investigators want to evaluate the patient's sense of well being and quality of life.

Clinical Trial of Pentoxifylline in Patient With Cirrhosis [Completed]
In patients with cirrhosis and liver failure, pro-inflammatory cytokines (TNF alpha) might be responsible of severe complications and death. Thus, the prevention of cytokine production should prevent complications and mortality.

The aim of this study is to study the 2 months survival rate in patients with severe

cirrhosis (Child-Pugh C) with pentoxifylline - an inhibitor of cytokine production. The 6

month mortality, the proportion of transplanted patients, the occurrence of complications (bacterial infection, renal failure, hepatic encephalopathy and gastrointestinal bleeding),

plasma cytokine levels and fibrotest - a marker of fibrosis - will be also studied. This is a

multicenter double blind randomized trial with a placebo.

All adult patients with severe cirrhosis might be randomized after written consent. Patients with severe carcinoma, intolerance or contraindication to pentoxifylline will not be included. Patients receive either pentoxifylline or placebo 3 times a day for 6 months. Three hundred and forty two patients are necessary to decrease mortality rate by 50% at 2 months in a beta risk of 10% and an alpha risk of 5%. Patients will be seen every month.

Efficacy of Combined Pentoxifylline and Conventional Immunosuppressive Regimens on Rapidly Progressive Glomerulonephritis [Recruiting]
We have recently demonstrated that pentoxifylline (PTX) has the potential to treat severe glomerular inflammation in a rat model of accelerated anti-glomerular basement membrane glomerulonephritis. This study aims to investigate the therapeutic effects of combined pentoxifylline and conventional immunosuppressive regimens on patients with rapidly progressive glomerulonephritis.

Pentoxifylline (Trental) as a Modulator of Tumor Necrosis Factor and of HIV Replication in Patients With AIDS [Completed]
To determine whether pentoxifylline lowers tumor necrosis factor (TNF) levels in AIDS patients. Pentoxifylline decreases tumor necrosis factor (TNF), and therefore should decrease such TNF-intensified events as cachexia, enhanced HIV expression, and inhibition of zidovudine (AZT) activity.

more trials >>


Page last updated: 2014-12-01

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2014